In contrast, RCC solid tumors are highly immunogenic with abundant T-cell lymphocytic infiltration, and immunotherapies such as IL-2 and IFN-alpha are among the most successful systemic treatments for RCC patients [7, 8]. Here, IL2 is linked to renal cell carcinoma.